GNLX CIK: 1231457

GENELUX Corp

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY22 to FY25
millions USD
FY21:
–
FY22:
−3.57
FY23:
−20.3
FY24:
−21.2
FY25:
−25.3
Change from FY22 to FY25
millions USD
FY21:
–
FY22:
−0.05
FY23:
−14.7
FY24:
−8.13
FY25:
12.1
Change from FY22 to FY25
millions USD
FY21:
–
FY22:
−0.48
FY23:
44.0
FY24:
28.5
FY25:
9.90
millions USD
FY21:
–
FY22:
−4.10
FY23:
9.02
FY24:
−0.85
FY25:
−3.23
(positive)
Change from FY21 to FY25
millions USD
FY21:
−6.59
FY22:
−3.62
FY23:
−21.3
FY24:
−21.6
FY25:
−26.4

All amounts in millions USD FY21: figures supplemented from Twelve Data because the SEC filings do not reach back this far. Data sources:SEC EDGARTwelve Data